Jean, a 19-year-old patient living with diabetes in Kigali, Rwanda, recently had his eyes screened at the Rwanda Diabetes Association clinic using Cybersight AI technology. He was relieved to know immediately that he was not showing any signs of disease. Of learning the news, he said, “I will continue taking care of myself and following the recommendation from my health care worker so my eyes don’t get damaged from the diabetes.”
Over the past three years, Orbis built Cybersight AI and deployed the technology in partner hospitals in Rwanda and Vietnam using AWS cloud services. Now, with expanded support from AWS, we’re establishing a new instance of Cybersight AI in the AWS Africa (Cape Town) region, which will improve the performance of eye clinics across Africa.
Thanks to the award, Cybersight AI will be trained to take advantage of new, larger, and more diverse datasets, ensuring the most accurate results. The project will also add the detection of a third eye disease, diabetic macular edema, another leading cause of vision loss in people with diabetes.
Nicolas Jaccard, Orbis Principal Architect, Telehealth and Program Technology says: “Cybersight AI, Orbis’s state-of-the-art technology, is a proven, effective and accessible technology to screen for diabetic retinopathy and glaucoma. The tool analyzes images of the back of the eye and, within seconds, indicates whether the patient shows signs of glaucoma or diabetic retinopathy. This technology is more scalable, cheaper and faster than current models that require a human grader. With this grant, Orbis will expand this revolutionary tool to more areas without access to quality eye care.”